RB1 and astrocytoma (excluding glioblastoma): Meanwhile, other molecular biomarkers indicating worse outcome in IDH‐mutant astrocytoma, including NOTCH1 mutations and incomplete resections in oligocytoma and PIK3R1 mutations, RB1 mutations and CDK4 mutations and amplifications in astrocytoma.26, 27